Episode
From fragile skin to living medicine: Lessons from RDEB
- Podcast
- BioSpace
- Published
- Jun 18, 2026
- Duration seconds
- 1303
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/from-fragile-skin-to-living-medicine-lessons-from-rdeb/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/biospace-6696251/from-fragile-skin-to-living-medicine-lessons-from-rdeb.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this episode of Denatured, you'll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We examine how recessive dystrophic epidermolysis bullosa serves as a model for cell and gene therapy, and what this ultra-rare disease teaches us about scaling advanced treatments for the future. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Mark Lowdell , CSO & Co-Founder, INmuneBio Inc Vishwas Seshadri , CEO & Director, Abeona Therapeutics Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.